Approved comparison material connected to this topic.
6 total recordsSource comparisons are presented without a generated winner.
Thymosin Alpha-1 T-cell maturation, Treg upregulation, cytokine modulation 1.6mg SC twice weekly Reduces pro-inflammatory cytokines (IL-6, TNF-α), improves NK cell function, addresses immune dysregulation driv…
Stanford Open-Label Trial (2023) 1.6mg SC twice weekly 16 weeks 47% reduction in Chalder Fatigue Scale; CD4+/CD8+ ratio normalized in 68% of subjects Gold-standard dosing. Most reproducible results across tria…
Standard Tα1 Monotherapy 1.6mg subcutaneous twice weekly 8–12 weeks for 30% FSI reduction Th1 polarization, NK cell activation, Treg expansion Best for patients with isolated immune dysfunction and low baselin…
Standard Therapeutic 1.6mg SC twice weekly 12-16 weeks T-cell modulation + moderate mitochondrial support 60-70% in inflammatory phenotype Gold standard for post-viral fatigue with documented immune activation…
Thymosin Alpha-1 TLR-9 activation, Th1/Treg differentiation Phase II: 47% functional improvement at 12 weeks (Stanford, 2026) 1.6mg SC twice weekly CD4+ T-cells, NK cells, cytokine balance (IL-2, IFN-γ) Strong…
When evaluating Thymosin Alpha-1 sources for chronic fatigue research, five factors determine whether the peptide will produce reliable, reproducible biological outcomes. Purity (HPLC Verified) >98% with third…